Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of QCC374 in pulmonary arterial hypertension
2016-001411-20Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of QCC374 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of QCC374. Started Jan 2017; status: terminated.
02
Drugs
QCC374
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2016-001411-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001411-20.